Association between estimated glucose disposal rate and the risk of MAFLD in American adults: a cross-sectional study

美国成年人估计葡萄糖处置率与代谢相关脂肪性肝病风险之间的关联:一项横断面研究

阅读:1

Abstract

The estimated glucose disposal rate (eGDR), as a novel metric of insulin resistance (IR), has been demonstrated to correlate with hepatic steatosis in patients with diabetes. Although IR is considered as a factor affecting lipid metabolism, the correlation between eGDR and metabolic associated fatty liver disease (MAFLD) is still unclear. Data from the 2017-2020 National Health and Nutrition Examination Survey (NHANES) were employed in this cross-sectional study designed to examine the association between eGDR and MAFLD through the application of weighted multivariate logistic regression model. The nonlinear relationship was described utilizing restricted cubic spline (RCS). Subgroup analysis was performed to assess the consistency of the results and causal mediation analysis was employed to explore potential mediators. The study included 3,585 participants, 2,002 of whom diagnosed MAFLD, with a prevalence rate of 55.84%. After adjusting for all confounding factors, the risk of MAFLD decreased by 19% with each unit increase in the eGDR (odds ratio [OR] 0.81, 95% confidence interval [CI] 0.76, 0.88, P < 0.0001). Analysis of eGDR in quartiles further supported this finding. The restricted cubic spline analysis revealed a significant nonlinear negative association between eGDR and MAFLD. Causal mediation analysis indicated that the relationship between eGDR and MAFLD was partially mediated by the atherogenic index of plasma (AIP), with a mediation ratio of 8.75%. Our results demonstrate that eGDR has a significant nonlinear negative association with the prevalence of MAFLD, in which AIP plays a mediating role, offering new insights into the prevention and management of MAFLD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。